Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nuvectis Pharma (NVCT) Net Income towards Common Stockholders (2021 - 2026)

Nuvectis Pharma has reported Net Income towards Common Stockholders over the past 6 years, most recently at -$6.0 million for Q1 2026.

  • Quarterly results put Net Income towards Common Stockholders at -$6.0 million for Q1 2026, down 13.47% from a year ago — trailing twelve months through Mar 2026 was -$29.6 million (down 46.76% YoY), and the annual figure for FY2025 was -$28.9 million, down 51.95%.
  • Net Income towards Common Stockholders reached -$6.0 million in Q1 2026 per NVCT's latest filing, up from -$7.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$2.9 million in Q1 2022 and bottomed at -$9.9 million in Q3 2025.
  • Median Net Income towards Common Stockholders over the past 5 years was -$5.9 million (2022), compared with a mean of -$5.6 million.
  • Peak annual rise in Net Income towards Common Stockholders hit 39.9% in 2022, while the deepest fall reached 12695.65% in 2022.
  • Over 5 years, Net Income towards Common Stockholders stood at -$6.7 million in 2022, then grew by 1.11% to -$6.6 million in 2023, then grew by 5.65% to -$6.2 million in 2024, then decreased by 17.06% to -$7.3 million in 2025, then increased by 17.28% to -$6.0 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for NVCT at -$6.0 million in Q1 2026, -$7.3 million in Q4 2025, and -$9.9 million in Q3 2025.